Onset and duration of inhibition of ipratropium bromide nasal spray on methacholine-induced nasal secretions.
We performed a randomized, double-blind, placebo-controlled cross-over study with two different concentrations of ipratropium bromide (Atrovent) nasal spray to evaluate its onset and duration of inhibition. Twenty-four subjects with perennial rhinitis participated in the trial. Fifteen minutes to 12 hours after administration of ipratropium bromide (42 or 168 micrograms/nostril) or placebo nasal spray, methacholine challenges were performed and nasal secretion weights measured. After placebo administration the effect of methacholine remained unchanged over the 12-h-period. Both the 42 and 168 micrograms/nostril doses significantly inhibited the nasal hypersecretions induced by methacholine challenge within 15 min of treatment (P < 0.05). The 168 micrograms dose of ipratropium bromide continued to significantly reduce secretion weights through 6 hours, but the effectiveness of the 42 micrograms dose disappeared within 3 h. In addition to having a longer duration, the 168 micrograms/nostril dose produced approximately twice the inhibitory effect of the 42 micrograms dose.
Johns Hopkins University School of Medicine, Department of Medicine (Division of Clinical Immunology), Baltimore, MD 21224.
M
M
Wagenmann
F M
FM
Baroody
R
R
Jankowski
J C
JC
Nadal
M
M
Roecker-Cooper
C C
CC
Wood
R M
RM
Naclerio
D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D009241:Ipratropium / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D016210:Methacholine Chloride; D008875:Middle Aged; D009297:Nasal Mucosa / Q000187:drug effects* / Q000378:metabolism*; D009299:Nasal Provocation Tests; D009330:Nebulizers and Vaporizers; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000503:physiopathology
D016210:Methacholine Chloride; D009241:Ipratropium